Primary Pulmonary Hypertension News - Menu
Basket bingo to benefit two Scout leaders with illnesses
By SHARI SANGER
Evening Sun Reporter
June 10, 2005 - Pam Peck knew it was just a matter of time. The disease that claimed the lives of the Hanover woman's sister and father has now turned her own life into a daily struggle.
As were her family members before her, Peck has been diagnosed with primary pulmonary hypertension - a rare lung disorder in which the blood pressure in the pulmonary artery rises far above normal levels for no apparent reason.
It forces the heart to work much harder, Peck explained.
The 41-year-old can't remember the last time she went shopping or for a walk because she loses her breath so easily. She gets dizzy spells and has trouble walking up and down stairs. She gets stressed and tires quickly.
Peck has been unable to return to her job as an emotional support teacher at Hoffman Homes between Littlestown and Gettysburg.
"My disease has totally changed my life," she said.
Her condition began in December, about two weeks before Christmas.
And since February, she has been unable to help with her Daisy Girl Scout troop at St. Matthew Lutheran Church in Hanover.
"I really miss everything. I'm just waiting for the day I can get back and involved in things again," Peck said. "It upsets me, but I'm determined my disease is not going to control my life. I'm going to control my disease."
Her sister and father weren't so fortunate.
Her sister, Kim Peck, was 24 when the condition claimed her life some 20 years ago, Peck said. Doctors diagnosed her with everything but PPH and when they finally discovered what it was, medicine had to be shipped from New England.
Kim died one day before the medication reached her, Peck said.
Her father, James Peck, died of the same disease eight years ago at age 57. Other complications, including diabetes, worsened his condition, Peck said.
Peck also had a brother who died at 6 months old. Doctors said the boy more than likely had PPH, Peck said.
Her mother, older sister, younger sister and younger brother have no trace of the disease.
With PPH well-known in her family, Peck knew what she was up against. But that didn't minimize the shock she felt when she was diagnosed.
"Before August I was doing fine ... and all of a sudden everything was taken away from me," she said. "I knew it was going to happen. It was just a matter of time."
Years ago, doctors gave patients with pulmonary hypertension two years to live. Now, it's five or more years, Peck said.
Peck gets the pressure measured in her heart and lungs and travels three hours for monthly visits at the Hospital of the University of Pennsylvania in Philadelphia, where doctors monitor her condition.
She takes a Tracleer pill twice a day to combat her symptoms. But it could take weeks to several months before the drug kicks in, she said. Her doctors are trying to get her insurance company to cover the cost of a second medication, Ventavis, that's supposed to work more effectively.
"It's been a challenge," Peck said.
And the challenge has come in the form of medical and financial complications.
That's why Jane Scull wanted to help.
Scull and Peck played volleyball together in high school but lost touch over the years. They were reunited when Scull's daughter joined the Girl Scout troop that Peck is leader of at the church.
"Pam is so sweet and the girls love her so much," Scull said. "You feel very helpless that you can't do anything medically to help, but maybe there is a way to help financially."
Scull has organized a basket bingo to be held at 2 p.m. Sunday at the Porter Sideling Fire Co. The proceeds will be split among Peck and another Girl Scout leader at the church who is also facing a serious medical condition. That leader declined to be interviewed for this story.
Peck said her family, friends and acquaintances have been very supportive and she was surprised to hear of the fund-raiser.
"I'm not the kind of person to draw attention to myself, so it's been a little difficult," she said. "But I love the idea and I'm so glad she's doing it."
Peck is planning to make an appearance at the basket bingo.
"It's overwhelming that people have gone out of their way to give me money and support and I'm always in their thoughts and prayers," Peck said. "It's just been amazing. I can never repay anyone for what they've done for me."
Contact Shari Sanger at ssanger@eveningsun.com .
AT A GLANCE:
What: Basket bingo
When: Sunday, June 12. Doors open at noon. Bingo starts at 2 p.m.
Where: Porters Sideling Fire Co.
Cost: Tickets are $15 and can be reserved or purchased at the door.
Donations: Cash donations for sponsoring baskets in the bingo are still needed.
For more information call Jane Scull at 637-0764.
ALLSCHWIL, Switzerland, Feb. 1, 2005 - Actelion Ltd (SWX: ALTN) announced today the publication of the scientific paper evaluating disease outcome of patients with advanced primary pulmonary arterial hypertension receiving Tracleer(bosentan).
CHICAGO--(BUSINESS WIRE)--Jan 31, 2005 - Fitch Ratings has affirmed Wyeth's 'A-' senior unsecured credit rating and 'F2' commercial paper rating.
MADISON, N.J., January 31, 2005 /PRNewswire-FirstCall/ -- Wyeth today reported results for the 2004 fourth quarter and full year. Worldwide net revenue increased 7% to $4.6 billion for the 2004 fourth quarter and 10% to $17.4 billion for the 2004 full year.
DALLAS, May 26, 2004 /PRNewswire/ -- The following was released today by Majority Counsel:
DENVER, May 24, 2004 /PRNewswire-FirstCall/ -- Myogen, Inc. (NASDAQ:MYOG) , a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, announced that Lewis Rubin, M.D. presented detailed results of AMB-220, the Company's Phase II safety and efficacy study of ambrisentan in patients with pulmonary arterial hypertension (PAH), at a mini symposium on "Emerging Therapies for PAH" at the American Thoracic Society (ATS) 2004 International Conference.
BEAUMONT, Texas, May 17, 2004 /PRNewswire/ -- The following was released today by Majority Counsel:
WESTON, Fla.--(BUSINESS WIRE)--Apr 30, 2004 - Coming on the heels of a Texas jury's $1 billion award to the family of a woman who died after taking one of the now banned phen-fen diet drugs, Freedland, Farmer, Russo & Sheller PL await a trial date for a strikingly similar case against Wyeth-Ayerst Laboratories.
MADISON, N.J., April 27, 2004 /PRNewswire-FirstCall/ -- Wyeth (NYSE:WYE) said today it will appeal today's verdict in the case of Jerry Coffey (representing the estate of Cynthia Cappel-Coffey), et al. v. Wyeth, et al.
BEAUMONT, Texas, April 27 /PRNewswire/ -- The following was released today by Majority Counsel:
A Beaumont, Texas jury today returned a more than $1 billion verdict against Wyeth-Ayerst Laboratories in a landmark Fen-Phen trial. Experts predict that this outcome against drug-maker Wyeth will set the standard by which the company will be judged in the tens of thousands of Fen-Phen cases currently in the court system awaiting trial dates.
WESTON, Fla.--(BUSINESS WIRE)--March 22, 2004--After almost a decade of stories of death and illness, billions of dollars in settlements, and persistent fears about Phen-Fen's damaging effects on those who've used it, news is emerging about lingering health risks related to the once-popular diet drug.
ALLSCHWIL/BASEL, SWITZERLAND - March 2, 2004 - Actelion Ltd (SWX: ATLN) today announced its financial results for the year 2003. With net revenues of CHF 307.5 million (FY 2002: CHF 132.4 m) and operating expenses of CHF 309.2 million (FY 2002: 164.5 m), the company reported an operating loss of CHF 1.7 million (FY 2002 loss: 32.0 m), mainly the result of a one-time In-Process R&D charge, related to the acquisition of Axovan in late 2003.
WEST SUSSEX, England, Oct. 24, 2003--Profile Therapeutics plc ("Profile"), which develops and commercialises specialist inhaled therapies, is delighted to announce the signing of an agreement with Schering Health Care Ltd. ("Schering"), a division of Schering AG.
ALLSCHWIL/BASEL, Switzerland, Sept. 2, 2003 - Actelion Ltd (SWX: ATLN) today announced results of a study assessing its oral dual endothelin receptor antagonist (ERA) Tracleer® (bosentan) in the treatment of pulmonary arterial hypertension (PAH) related to HIV (human immunodeficiency virus) infection.
ALLSCHWIL/BASEL, SWITZERLAND - May 19, 2003 - Actelion Ltd (SWX: ATLN) today announced the analysis of long-term follow-up data of primary pulmonary hypertension patients from Tracleer® pivotal registration studies.
HAYWARD, Calif. and ATLANTA, Sept. 26, 2002 /PRNewswire-FirstCall/ -- Aradigm Corporation (NASDAQ: ARDM) , a leader in pulmonary drug delivery and geneRx+, an innovator in protein and gene-based technologies, today
SACRAMENTO, Calif., Jan. 10, 2002 -- People who have opted out of the class-action lawsuit against American Home Products and
SACRAMENTO, Sept. 10, 2001 -- Two wrongful death complaints filed today in California could signal a renewed wave of lawsuits against American Home Products just as the pharmaceutical company coaxes investors back with predictions that its legal troubles over Fen-Phen/Redux are coming to an end.
SACRAMENTO, Calif., Sept. 10, 2001 -- Donald Holmes of San Juan Bautista was the 63-year-old owner of a trucking company
MADISON, N.J., Jan. 25, 2001 -- American Home Products Corporation (the Company) (NYSE: AHP) today reported net revenue and results of operations for the 2000 fourth quarter and full year.
TORONTO, Nov. 22, 2000 - Access to justice for more than 155,000 Canadians who took the diet pills Ponderal and Redux which are alleged to cause serious illnesses is now a reality following an important ruling released today from Madam Justice Susan Gray of the Ontario Divisional Court.
MADISON, N.J., Oct. 19, 2000 -- American Home Products Corporation (the Company) (NYSE: AHP) today reported sales and earnings results for the 2000 third quarter and first nine months.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 28, 2000 -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that results of its Phase III clinical trial of Uniprost (also known as UT-15) for pulmonary hypertension -- the largest double blinded placebo-controlled pulmonary hypertension study -- were presented today at a satellite symposium organized for clinicians attending the European Society of Cardiology's annual meeting in Amsterdam, The Netherlands.
Research Triangle Park, NC, (May 2, 2000)-Glaxo Wellcome Inc. announced today that Flolan‚ brand epoprostenol sodium for Injection, a treatment for severe cases of primary pulmonary hypertension (New York Heart Association (NYHA) classes III & IV), has now received approval for a new indication, the long-term intravenous treatment of pulmonary hypertension secondary to scleroderma spectrum of diseases (PH/SSD, NYHA classes III & IV) for patients who do not respond to conventional therapy.
HOUSTON, March 13, 2000 -- Fleming & Associates, L.L.P., lead counsel for two severely injured Sioux Falls, South Dakota, women who ingested Fen-Phen, has successfully petitioned the court to order John R. Stafford, chairman, president and CEO of American Home Products Corporation (NYSE: AHP) (AHP), to undergo an immediate deposition by plaintiffs’ attorney George M. Fleming.
|